Jason Hannon joined Mainstay Medical as Chief Executive Officer and as a Director in October 2017. Mr. Hannon has extensive experience in the medical devices industry, particularly in the areas most critical to the future success of Mainstay: commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture.
Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world. During his 12 years at the company, and prior to becoming COO, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. During his tenure, the company’s commercial presence was expanded globally to more than 40 countries, revenue grew from $61M to almost $1 billion, and the product portfolio expanded to over 100 products.
Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.
Chief Operating Officer
Prashant Rawat has worked more than 20 years in active implantable medical device companies (Guidant, CVRx, CSF Therapeutics) and brings broad experience in managing global engineering teams and achieving international regulatory product approvals. Mr. Rawat is responsible for all research and development, coordination of manufacturing and distribution, clinical operations, the Quality Management System, and expansion of the company’s Intellectual Property portfolio.
Mr. Rawat’s extensive international experience in the medical device industry includes building internal R&D teams and relationships with foreign institutions and companies for joint research, product development and manufacturing. He also has broad experience in guiding new technology through the clinical and regulatory processes in Europe, Asia and the United States. While Technology Fellow and Manager of the Advanced Technology Group at Boston Scientific’s Cardiac Rhythm Management group, he was responsible for development of the world’s first implantable long-range telemetry system. Since then, he worked as an advisor to CVRx, a private neurostimulation company developing an implantable device for treatment of high blood pressure, and was VP Research and Development at CSF Therapeutics, a venture capital-backed spinoff from the Cleveland Clinic developing a novel invasive therapy to improve blood flow in stroke victims.
Mr. Rawat has a Bachelor of Engineering in Electronics Engineering and Telecommunications from the Maharaja Sayajirao University, Gujarat, India, and a Master of Science in Electrical Engineering and Applied Physics from Case Western Reserve University, Ohio, U.S. He is the inventor on over 25 patents and patent applications.
Chief Financial Officer
Mr. Onaitis has worked with dynamic healthcare businesses for 20 years, ranging from global multinationals including Biogen Idec and Elan Pharmaceuticals, to innovative specialty pharmaceutical companies such as Ignyta, Trius Therapeutics, and Somaxon Pharmaceuticals. He most recently served as Chief Financial Officer of Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies. During his tenure at Cidara, the company raised over $185 million and successfully progressed its lead program into late-stage clinical trials. Cidara is one of four publicly-traded healthcare companies at which Mr. Onaitis has been a senior executive. His experience includes building finance teams, leading numerous public and private financings, mergers and acquisitions and strategic collaborations, and the management of finance, accounting, business development, manufacturing, legal, and human resource functions.
Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.
Jan Pieter Heemels
Vice President Marketing
Jan Pieter Heemels has in excess of 25 years of international experience in medical devices (Cordis, Guidant, Boston Scientific, Spinal Modulation), including five years in Neuromodulation. His current responsibilities include, market and key account development, reimbursement in major global market, marketing and communication, alignment of the clinical strategy with the companies commercial objectives, and development and expansion of the Company's Intellectual Property portfolio.
Mr. Heemels’ broad international experience includes managing new product definitions, clinical trials, sales and market development for Cardiac Rhythm Management products (implantable cardiac pacemakers and defibrillators) in Guidant and Boston Scientific. Subsequently he was a consultant to privately held start-up companies in Neuromodulation (Spinal Modulation) and medical imaging for urology (Advanced Medical Diagnostics). Since joining Mainstay in early 2011, he has been instrumental in advancing the Feasibility Study and preparing for commercialisation of ReActiv8.
Mr. Heemels holds a Master of Science degree in physics from the VU University in Amsterdam and a Master of Business Administration degree from the University of Minnesota. He is named inventor on 9 key patents and patent applications in the field of biomedical engineering, including neuromodulation.
SVP Corporate Affairs and Chief Legal Officer
Tom Maher joined Mainstay Medical as General Counsel directly following the company’s IPO in 2014. Tom is an Irish qualified corporate and transactional lawyer with over 15 years’ experience in the international life sciences industry. His responsibilities include corporate matters, the management and operation of the company’s legal function, the role of Company Secretary, and the co-ordination of the prosecution of the company’s intellectual property portfolio.
Mr Maher was previously General Counsel at Amarin Corporation (NASDAQ), and Vice President of Legal Affairs at Elan Corporation (NYSE), both of which were at different stages dual listed in Ireland and the US.
Mr Maher qualified as an Irish solicitor while working with A&L Goodbody Solicitors and he holds a law degree from Trinity College, Dublin.
Vice President Clinical Affairs
Diane Burnside has over 32 years of experience in the medical device industry, with seven years specifically in active implantable medical devices. Ms. Burnside brings broad experience in clinical leadership, including strategic direction, design and execution of clinical programs to obtain CE Mark certifications and PMA approvals. Her responsibilities comprise planning and implementing strategy, procedures and practice in clinical programs to gain global regulatory and reimbursement approvals.
Ms. Burnside has worked in start-up and large multinational companies, contributing to all phases of product development including research, pre-clinical and clinical evaluations, post-market studies, post-approval studies and international clinical programs. Ms. Burnside recently served as Vice President of Clinical Affairs at Kspine, where she was instrumental in setting up and managing an international clinical trial for studying the effects of a spinal implant for the treatment of pediatric scoliosis. Previous to that, she held clinical leadership positions at Neurostream/OttoBock, Uromedica, Medtronic Neurological division and Boston Scientific. She has overseen clinical programs in the United States, Europe, Australia, and Canada that have led to the approval of multiple products. Ms. Burnside has been involved in 5 PMA approvals, including three panel meetings, of neuromodulation for Parkinson’s disease, and cardiologic, vascular and urological stents.
Ms. Burnside holds an Applied Science degree from the University of Minnesota.
Vice President Market Development
With over 15 years of experience in the health sector, Gunther Peeters previously held the position of Vice President of Europe at Vexim SA, a medical device company specializing in minimally invasive treatment of traumatic spine pathologies. During his role at Vexim, which including aligning and accelerating commercialisation in Europe, Vexim’s Spinejack became a market leader in the spine trauma market. (Vexim was acquired by Stryker at the end of 2017).
Prior to Vexim, he held the role of Director of Business Development and International Sales at Orthobion GmbH , a start-up developing accelerated technology for interbody spinal fusion devices. He was responsible for all commercial development in close collaboration with leading European spine surgeons. He started in the management of international sales and marketing for Spinal Kinetics. A company that was specialized in innovative motion preservation technology. In this role, he was responsible for the build-out of the international commercialisation, education about and marketing of the M6 Cervical and Lumbar discs, helping Spinal Kinetics to achieve a market leader status with more than 25,000 implants within 6 years. (Spinal Kinetics was acquired by Orthofix at the start of 2018). He began his career at Hexal, later acquired by Sandoz (Novartis Generics ) as a pharmaceutical sales representative.
Gunther has completed the Executive Master program in International Business Management from Vlerick Business School and a Master in Management from the London Business School.
Vice President, Managing Director, Germany
Wolfgang Frisch joined Mainstay Medical as VP and Managing Director, Germany in July 2018. Mr Frisch has 30 years’ experience in medical technology, including 20 in senior leadership positions in sales, market access, market development, and general management, having spent a combined 15 years with Stryker and Medtronic. In his various roles. Mr Frisch has experience in many medical technologies segments, such as large equipment at Dräger, implants, medical aids and complex consulting services at Stryker and Medtronic.
Mr Frisch most recently served on the executive board of Medtronic Germany, where he was also managing director for the strategic and tactical deployment of the sales organization in the entirety of Germany, and he led three directorate departments directly: Key Account Management, Market Access & Strategy, and Healthcare Policy & Governmental Relations.
At Stryker, Mr Frisch served as Director of Business Development for the DACH region, focusing on the development of care pathways for total endoprosthesis and the development of integrated care plans with health insurers.
Mr Frisch started his career at Dräger, where he was responsible for all sales departments, including large equipment sales and specialist service sales.
Mr Frisch has broad experience and expertise across all key areas of the German healthcare system.
He holds a diploma in electrical engineering from the University of Applied Sciences in Frankfurt.